DOCKET NO.: UPN-4929 **PATENT**

Application No.: 10/591,963

Office Action Dated: May 19, 2010

REMARKS

Claims 1, 3, and 6 have been amended and claims 2 and 7 have been canceled. Claims 8 and 9 are directed to the subject matter of claims 4 and 6 and have been added to depend from method claim 1. Support for the claim amendments may be found throughout the specification and particularly in paragraph [0024] and Figures 3-5. No new matter has been added. Upon entry of the above amendments, claims 1, 3-6, and 8-9 will be in the application.

Claim Rejections – 35 USC § 103(a)

Claims 1-3 and 7 stand rejected under 35 USC § 103(a) as allegedly being unpatentable as obvious over US 5,013,296 ("Buckberg") in view of US 6,267,747 ("Samson"). Claims 2 and 7 have been canceled, thereby obviating the rejections of these claims. These rejections as applied to amended claims 1 and 3 are traversed.

Independent claims 1 and 3 have been amended to clarify that the inserted membrane is opened "upon emergence from a distal end of the lumen" and the opened membrane is advanced "until it covers the aortic valve at a deployment position below the coronary arteries" thereby preventing the cardioplegia solution from entering the left ventricle through the aortic valve and trapping the cardioplegia solution above the membrane and below the cross-clamp so as to force the cardioplegia solution down the coronary arteries. Thus, the membrane is opened and moved into place downstream from the cardioplegia delivery position so as to prevent the cardioplegia solution from passing through an incompetent aortic valve into the left ventricle while simultaneously forcing the cardioplegia solution down the coronary arteries as desired. Such features are not shown or suggested by the cited references.

As noted in a previous reply, Buckberg discloses a conventional cardioplegia cannula that is inserted into the aortic root beneath a clamp for administration of cardioplegia solution. Such a device is quite similar to that illustrated in prior art Figure 2 of the present application. The examiner acknowledged at the bottom of page 2 of the Final Rejection that Buckberg does not disclose a lumen "adapted to accept a folded non-porous membrane to cover the aortic valve nor the use of such a membrane." Applicant further notes that Buckberg does not recognize or address the problem of leakage of cardioplegia solution into the left ventricle through the aortic valve during administration of the cardioplegia solution.

DOCKET NO.: UPN-4929 PATENT

Application No.: 10/591,963
Office Action Dated: May 19, 2010

To address such shortcomings in the teachings of Buckberg, the examiner again cites Samson's teachings of an aortic catheter that uses a balloon to occlude blood flow in the aortic root and concludes that one skilled in the art would have modified the cannula of Buckberg to deliver a balloon as taught by Samson to block the aortic root and aortic valve to prevent the aortic root from experiencing significant retrograde fluid pressure. Applicant respectfully disagrees with the examiner's conclusions from the teachings of Buckberg and Samson.

As is clear from Figure 5 of the present application and the related discussion in paragraph [0024] of the specification, the claimed methods and cannula address the problem of leakage through the aortic valve during cardioplegia delivery. Neither Buckberg nor Samson addresses this issue. Samson teaches that by delivering cardioplegia solution directly to the coronary arteries that Samson's aortic root balloon perfusion catheter purportedly does not cause significant retrograde fluid pressure that would cause cardioplegia solution to be forced through the aortic valve into the left ventricle. Applicant notes further that Samson does not account for an incompetent or open aortic valve that would leak even if "significant retrograde fluid pressure" were not created. Samson thus does not address the problem addressed by the claimed method and cannula.

Moreover, the geometry of the cannula disclosed by Samson would preclude the possibility of inserting a membrane through Samson's or Buckberg's catheter that would trap the cardioplegia solution "above the membrane and below the cross-clamp so as to force the cardioplegia solution down the coronary arteries" as claimed. As previously noted, Samson uses a distal flow control member in the form of a porous aortic root member that is configured to deliver the cardioplegia solution to the coronary ostia while occluding the ascending aorta. When in place, the cannula of Samson occludes the ascending aorta with the expanded balloon of the aortic root balloon perfusion catheter but does not provide anything to occlude the leakage of cardioplegia fluid through the aortic valve into the left ventricle. Also, as noted at column 6, lines 41-55, the porous root balloon is mounted distally and delivers the cardioplegia solution through a porous material 126 of the porous root balloon to provide a controlled volume of fluid that may perfuse the coronary arteries. Since Samson is concerned with controlling the flow of cardioplegia fluid to the aortic valve to avoid significant retrograde fluid pressure, it is clear that

DOCKET NO.: UPN-4929 PATENT

Application No.: 10/591,963 **Office Action Dated:** May 19, 2010

Samson did not teach or contemplate using a membrane to trap the cardioplegia solution above the membrane and below the cross-clamp so as to force the cardioplegia solution down the coronary arteries as claimed. In other words, Samson relies upon low pressure perfusion that "does not challenge the competence of the aortic valve" instead of blocking the aortic valve with a membrane as claimed.

Accordingly, even if one skilled in the art would have known to combine the teachings of Buckberg and Samson as the examiner alleges, the claimed method and cardioplegia cannula would not have resulted for at least two reasons. First, since Samson uses low pressure perfusion that "does not challenge the competence of the aortic valve," Samson would not motivate one skilled in the art to block the aortic valve as claimed to prevent fluid flow into the left ventricle absent a recognition that an incompetent aortic valve would allow leakage into the left ventricle. Samson provides no such teachings. Second, neither Buckberg nor Samson teaches advancing the membrane through a lumen and delivering the opened membrane to the aortic valve as claimed. Withdrawal of the rejection of claims 1-3 and 7 as being unpatentable as obvious over Buckberg and Samson is thus appropriate and is solicited.

Claims 4-6 stand rejected under 35 USC § 103(a) as allegedly being unpatentable as obvious over Buckberg and Samson further in view of US 6,638,293 ("Makower"). These rejections are also traversed.

As claims 4-6 depend from claim 3, these claims are patentable over Buckberg and Samson for at least the reasons set forth above with respect to claim 3. Moreover, Applicant submits that Makower does not provide any teachings that address the aforementioned deficiencies in the teachings of Buckberg and Samson. The examiner alleges that Makower teaches an umbrella membrane that is opened either using a wire or that springs open where both the wire and umbrella are made of nitinol and that such teachings would have been combined with the teachings of Buckberg and Samson by one skilled in the art to arrive at the claimed methods and cardioplegia cannula. Applicant respectfully disagrees.

Makower discloses a variety of lumen blocking apparatuses that may be delivered transluminally through the patient's vasculature. However, like Buckberg and Samson, Makower does not recognize the problem of aortic valve leakage or provide any solution to such

DOCKET NO.: UPN-4929 PATENT

Application No.: 10/591,963 **Office Action Dated:** May 19, 2010

leakage during administration of cardioplegia solution. Also, Makower does not teach a method or cardioplegia cannula configuration whereby the cardioplegia solution is trapped above the deployed membrane and below the cross-clamp so as to force the cardioplegia solution down the coronary arteries as claimed. Accordingly, even if one skilled in the art would have used the teachings of Makower to advance the membrane through a lumen and deliver the opened membrane to the distal end of the lumen, the teachings of Makower would have taught one skilled in the art to do this to stop blood flow, not to block the aortic valve as claimed to prevent fluid flow into the left ventricle. In other words, Makower does not overcome Samson's contrary teachings of using low pressure perfusion that "does not challenge the competence of the aortic valve" instead of advancing a membrane through a lumen to cover the aortic valve as claimed. Makower does not overcome the deficiencies in the teachings of Buckberg and Samson and withdrawal of the rejection of claims 4-6 is thus appropriate. New claims 8 and 9 are believed to be allowable based on the same reasoning.

For at least the reasons set forth herein, claims 1, 3-6, and 8-9 are believed to be allowable over Buckberg, Samson, and Makower. None of the cited art suggests occluding the aortic valve to prevent the leakage of cardioplegia solution into the left ventricle via the aortic valve as claimed. Withdrawal of all rejections is solicited.

CONCLUSION

In view of the foregoing amendments and remarks, Applicants respectfully submit that the claims, as amended, are in a condition for allowance. Applicants respectfully request the issuance of a Notice of Allowability.

Date: August 19, 2010 /Michael P. Dunnam/

Michael P. Dunnam Registration No. 32,611

Woodcock Washburn LLP Cira Centre 2929 Arch Street, 12th Floor Philadelphia, PA 19104-2891 Telephone: (215) 568-3100 Facsimile: (215) 568-3439